parallel randomized trial
S003439
Other conditionsS003439
Design
Conduct and analysis
Arms
| Arm | Treatment | Background | Randomized | Analyzed | Completed treatment |
|---|---|---|---|---|---|
| A1 | semaglutide Velgia semaglutide 0.5 mg single dose | lifestyle: not reported | 15 | ||
| A2 | semaglutide Wegovy semaglutide 0.5 mg single dose | lifestyle: not reported | 15 | ||
| A3 | semaglutide Velgia semaglutide 2.4 mg single dose | lifestyle: not reported | 15 | ||
| A4 | semaglutide Wegovy semaglutide 2.4 mg single dose | lifestyle: not reported | 15 |
Baseline characteristics
As printed in the trial reports or registry, per arm or for the whole trial.
| Characteristic | Statistic | Velgia semaglutide 0.5 mg single dose A1 | Wegovy semaglutide 0.5 mg single dose A2 | Velgia semaglutide 2.4 mg single dose A3 | Wegovy semaglutide 2.4 mg single dose A4 | Whole trial ALL |
|---|---|---|---|---|---|---|
| age dose:0.5mg | mean (years) | 45.13 | ||||
| age dose:2.4mg | mean (years) | 43.87 | ||||
| bmi dose:0.5mg | mean (kg/m2) | 26.35 | ||||
| bmi dose:2.4mg | mean (kg/m2) | 26.81 | ||||
| female dose:0.5mg | n | 22 | ||||
| female dose:0.5mg | percent | 72.33 | ||||
| female dose:2.4mg | n | 9 | ||||
| female dose:2.4mg | percent | 30 | ||||
| weight dose:0.5mg | mean (kg) | 75.71 | ||||
| weight dose:2.4mg | mean (kg) | 82.89 |
Results
20 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
Serious adverse events (4 lines; O25)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 0 / 15 | not stated; randomized; R0047620:Results | ||||
| A2 | events | 0 / 15 | not stated; randomized; R0047620:Results | ||||
| A3 | events | 0 / 15 | not stated; randomized; R0047620:Results | ||||
| A4 | events | 0 / 15 | not stated; randomized; R0047620:Results |
Discontinuation due to adverse events (4 lines; O26)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 0 / 15 | not stated; randomized; R0047620:Results | ||||
| A2 | events | 0 / 15 | not stated; randomized; R0047620:Results | ||||
| A3 | events | 0 / 15 | not stated; randomized; R0047620:Results | ||||
| A4 | events | 0 / 15 | not stated; randomized; R0047620:Results |
Nausea (2 lines; O27A)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 0 / 15 | not stated; randomized; R0047620:Results | ||||
| A2 | events | 0 / 15 | not stated; randomized; R0047620:Results |
Vomiting (2 lines; O27B)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 0 / 15 | not stated; randomized; R0047620:Results | ||||
| A2 | events | 0 / 15 | not stated; randomized; R0047620:Results |
Diarrhea (2 lines; O27C)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 0 / 15 | not stated; randomized; R0047620:Results | ||||
| A2 | events | 0 / 15 | not stated; randomized; R0047620:Results |
Constipation (2 lines; O27D)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 0 / 15 | not stated; randomized; R0047620:Results | ||||
| A2 | events | 0 / 15 | not stated; randomized; R0047620:Results |
Discontinuation due to gastrointestinal adverse events (4 lines; O27E)
| Week | Arm | Statistic | Estimate | SE or SD | 95% CI | Events / N | Detail |
|---|---|---|---|---|---|---|---|
| A1 | events | 0 / 15 | not stated; randomized; R0047620:Results | ||||
| A2 | events | 0 / 15 | not stated; randomized; R0047620:Results | ||||
| A3 | events | 0 / 15 | not stated; randomized; R0047620:Results | ||||
| A4 | events | 0 / 15 | not stated; randomized; R0047620:Results |